China Resources Pharmaceutical Group (FRA:640) 5-Year EBITDA Growth Rate : 7.70% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group 5-Year EBITDA Growth Rate?

China Resources Pharmaceutical Group's EBITDA per Share for the six months ended in Dec. 2024 was €0.14.

During the past 12 months, China Resources Pharmaceutical Group's average EBITDA Per Share Growth Rate was 4.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 8.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 7.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of China Resources Pharmaceutical Group was 12.50% per year. The lowest was -3.80% per year. And the median was 5.30% per year.

Competitive Comparison of China Resources Pharmaceutical Group's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Pharmaceutical Group's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

China Resources Pharmaceutical Group 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

China Resources Pharmaceutical Group (FRA:640) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

China Resources Pharmaceutical Group 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (FRA:640) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

03320:Hong Kong 640:Germany

Address

26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG

Website

https://www.crpharm.com

China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2024, the medical distribution business accounts for 82.8% of its total revenue. CR Pharma's manufacturing business, 18.0% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.

China Resources Pharmaceutical Group Headlines

No Headlines